Literature DB >> 7140872

Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels.

B Billing, R Dahlqvist, M Garle, Y Hörnblad, E Ripe.   

Abstract

The bronchodilating properties and side effects of theophylline and a beta 2-adrenoceptor stimulating drug (terbutaline) alone and in combination were studied in 10 adult asthmatic patients. Initially, each individual's pharmacokinetic parameters for theophylline were determined. On 3 separate days theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 microgram/ml, respectively) followed by the administration, at 1-h intervals, of incremental i.v. doses of terbutaline. It was shown that: 1. Theophylline caused a concentration-dependent increase in FEV1. Theophylline itself had no significant effect on objectively recorded skeletal muscle tremor or heart rate but enhanced the terbutaline-induced increase in tremor and heart rate. At the highest concentration (15 microgram/ml) two of the patients experienced nausea. 2. Terbutaline caused a concentration-dependent increase in FEV1, heart rate, and tremor. The plasma levels of terbutaline at the given doses did not differ significantly between individuals or within individuals at the different theophylline levels. 3. The combination of theophylline and terbutaline resulted in a mere additive effect on the bronchodilatation. At comparable bronchodilatation the combination of theophylline and terbutaline caused a lesser degree of side effects than each of the drugs alone.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7140872

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  13 in total

Review 1.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

2.  Tracheal relaxation from combinations of xanthines and of a beta 2-receptor agonist and xanthines.

Authors:  C G Persson; B Gustafsson
Journal:  Lung       Date:  1986       Impact factor: 2.584

Review 3.  Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma.

Authors:  R P Koopmans; R E Jonkers; M C Braat; C J van Boxtel
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

4.  Comparison of the in vitro dissolution properties and in vivo steady-state pharmacokinetics of two sustained-release theophylline preparations.

Authors:  J H Jonkman; W J Van der Boon; G Grasmeijer
Journal:  Pharm Weekbl Sci       Date:  1988-02-19

5.  Nocturnal oxygen saturation and body movement in asthmatics treated with controlled-release preparations of theophylline or terbutaline.

Authors:  P E Brander; A R Sovijärvi; T Salmi; A Hakulinen; H Poppius
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 7.  Interpretation of drug levels in acute and chronic disease states.

Authors:  E Perucca; R Grimaldi; A Crema
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

8.  Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline.

Authors:  J S Mann; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

9.  Additive bronchodilator effects of terbutaline and enprofylline in asthma.

Authors:  J B Rasmussen; E Lunell
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults.

Authors:  J Rosenborg; P Larsson; L Nyberg
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.